Cartherics and TiCARos have joined forces in a collaboration aimed at developing CAR-NK products for cancer treatment. TiCARos will generate CLIP-CAR constructs to be incorporated into Cartherics’ NK cells for assessing their function both in vitro and in vivo.
TiCARos specializes in developing CAR-T cell products for the treatment of solid and blood cancers using its unique CLIP-CAR approach. This approach modifies the CAR structure to stabilize the immune synapse between immune cells and target tumor cells, resulting in improved efficacy in models.
Cartherics’ CEO, Professor Alan Trounson, believes that combining TiCARos’ CLIP-CAR technology with Cartherics’ allogeneic NK cell platform has the potential to enhance the effectiveness of cancer therapies. By collaborating with innovative companies like TiCARos, Cartherics aims to build a leading portfolio of therapeutic products for cancer treatment. The collaboration between the two companies aims to develop a CAR-NK product targeting tissue factor for triple negative breast cancer and other challenging cancers.
Each company has nominated a specific tumor antigen to target with the CARs, with Cartherics focusing on tissue factor (TF) and TiCARos targeting CD19. The collaboration between the two companies aims to accelerate pipeline programs and expand the use of TiCARos’ technology beyond autologous cell therapies. If the research collaboration yields positive results, Cartherics and TiCARos will negotiate a development and commercialization agreement for their CAR-NK therapeutic approach.
